A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model

BACKGROUND: The four-component serogroup B meningococcal 4CMenB vaccine (Bexsero, GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12 months of age since September 2015. After 3 years, Public Health England (PHE) reported a 75% [95% confidence interval 64%; 81%] reducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Argante, Lorenzo, Abbing-Karahagopian, Victoria, Vadivelu, Kumaran, Rappuoli, Rino, Medini, Duccio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666080/
https://www.ncbi.nlm.nih.gov/pubmed/34895161
http://dx.doi.org/10.1186/s12879-021-06906-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666080/
https://www.ncbi.nlm.nih.gov/pubmed/34895161
http://dx.doi.org/10.1186/s12879-021-06906-x

Ejemplares similares